Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310413 · ClinicalTrials.gov registry record · Phase 3
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 842
- Enrollment target
NCT01310413 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 842 participants.
The verdict
NCT01310413, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 842 participants
- Enrollment target
Study Summary
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to \< 18 years of age.
Interventions
- BIOLOGICAL Saline placebo
- BIOLOGICAL Influenza A (H5N1) Virus monovalent vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 842 participants |
| Start Date | 2011-03-07 |
| Est. Completion | 2014-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01310413
The ClinicalTrials.gov registry entry for NCT01310413 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 842 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline placebo is the first listed.
NCT01310413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01310413 about?
NCT01310413 is a clinical study titled "Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age". This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to \< 18 years of age.
What is the current status of trial NCT01310413?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 842 participants. The study started on 2011-03-07. Estimated completion is 2014-01-26.
What interventions are being tested in trial NCT01310413?
The interventions under investigation include: Saline placebo (BIOLOGICAL), Influenza A (H5N1) Virus monovalent vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01310413?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.